Polymeric Pathogen-Like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus.
Adjuvants, Immunologic
/ pharmacology
Animals
Cell Line
Dogs
Immunity, Cellular
/ immunology
Immunity, Innate
/ immunology
Immunologic Memory
/ immunology
Influenza A virus
/ immunology
Intraepithelial Lymphocytes
/ immunology
Lung
/ immunology
Madin Darby Canine Kidney Cells
Mice
Mice, Inbred C57BL
Orthomyxoviridae Infections
/ immunology
Polylactic Acid-Polyglycolic Acid Copolymer
/ immunology
Toll-Like Receptor 4
/ immunology
CD4
CD8
adjuvants
influenza A virus
polyfunctional
tissue-resident memory
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
05
2020
accepted:
21
12
2020
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
13
4
2021
Statut:
epublish
Résumé
Eliciting durable and protective T cell-mediated immunity in the respiratory mucosa remains a significant challenge. Polylactic-co-glycolic acid (PLGA)-based cationic pathogen-like particles (PLPs) loaded with TLR agonists mimic biophysical properties of microbes and hence, simulate pathogen-pattern recognition receptor interactions to safely and effectively stimulate innate immune responses. We generated micro particle PLPs loaded with TLR4 (glucopyranosyl lipid adjuvant, GLA) or TLR9 (CpG) agonists, and formulated them with and without a mucosal delivery enhancing carbomer-based nanoemulsion adjuvant (ADJ). These adjuvants delivered intranasally to mice elicited high numbers of influenza nucleoprotein (NP)-specific CD8+ and CD4+ effector and tissue-resident memory T cells (T
Identifiants
pubmed: 33767689
doi: 10.3389/fimmu.2020.559382
pmc: PMC7986715
doi:
Substances chimiques
Adjuvants, Immunologic
0
Toll-Like Receptor 4
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
559382Subventions
Organisme : NIAID NIH HHS
ID : R21 AI149793
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124270
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124299
Pays : United States
Informations de copyright
Copyright © 2021 Kingstad-Bakke, Toy, Lee, Pradhan, Vogel, Marinaik, Larsen, Gates, Luu, Pandey, Kawaoka, Roy and Suresh.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS Pathog. 2017 May 22;13(5):e1006356
pubmed: 28542595
PLoS Pathog. 2016 Dec 20;12(12):e1006064
pubmed: 27997610
Science. 2013 Sep 13;341(6151):1246-9
pubmed: 23887873
Front Immunol. 2018 Mar 26;9:515
pubmed: 29632527
Nat Rev Immunol. 2012 Nov;12(11):749-61
pubmed: 23080391
Front Immunol. 2018 Nov 20;9:2692
pubmed: 30515169
Mol Immunol. 2019 Mar;107:142-164
pubmed: 30739833
J Gen Virol. 2011 Dec;92(Pt 12):2879-2888
pubmed: 21880840
Immunity. 2010 Jul 23;33(1):96-105
pubmed: 20637658
JCI Insight. 2016 Jul 7;1(10):
pubmed: 27468427
Immunotherapy. 2013 May;5(5):497-511
pubmed: 23638745
Cell Rep Med. 2020 Sep 22;1(6):100095
pubmed: 32984856
J Immunol. 2009 Mar 15;182(6):3469-81
pubmed: 19265125
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
J Leukoc Biol. 2014 Feb;95(2):215-24
pubmed: 24006506
Semin Immunol. 2018 Oct;39:14-21
pubmed: 29801750
J Immunol. 2011 Dec 1;187(11):5510-4
pubmed: 22058417
J Virol. 2008 Dec;82(24):12241-51
pubmed: 18842709
Mucosal Immunol. 2017 Jan;10(1):260-270
pubmed: 27049058
Immunol Cell Biol. 2017 Sep;95(8):651-655
pubmed: 28405016
J Neuroimmunol. 2014 May 15;270(1-2):13-21
pubmed: 24680062
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Mucosal Immunol. 2014 May;7(3):501-10
pubmed: 24064670
J Clin Invest. 2010 Feb;120(2):570-81
pubmed: 20051628
Med Microbiol Immunol. 1975 Dec 30;162(1):9-14
pubmed: 1214709
Immunity. 2018 Feb 20;48(2):214-226
pubmed: 29466754
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Oncotarget. 2016 Oct 25;7(43):70223-70231
pubmed: 27602959
Immunity. 2011 Dec 23;35(6):972-85
pubmed: 22177921
Trends Biochem Sci. 2016 Dec;41(12):1012-1021
pubmed: 27669650
Nat Immunol. 2016 Dec;17(12):1467-1478
pubmed: 27776108
ACS Biomater Sci Eng. 2017 Feb 13;3(2):169-178
pubmed: 33450793
Virol J. 2009 Mar 13;6:30
pubmed: 19284639
Mol Immunol. 2006 May;43(13):2045-50
pubmed: 16513171
Cell Rep. 2017 Jan 17;18(3):700-710
pubmed: 28099848
Sci Rep. 2018 Jul 19;8(1):10910
pubmed: 30026610
Pathogens. 2019 Apr 22;8(2):
pubmed: 31013616
Nature. 2011 Feb 24;470(7335):543-7
pubmed: 21350488
Mucosal Immunol. 2018 Jul;11(4):1265-1278
pubmed: 29545648
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669928
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Clin Vaccine Immunol. 2015 Sep;22(9):1004-12
pubmed: 26135973
Immunity. 2013 Nov 14;39(5):939-48
pubmed: 24238342
Front Immunol. 2016 May 19;7:195
pubmed: 27242800
Lancet. 2017 Aug 12;390(10095):697-708
pubmed: 28302313
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6115-20
pubmed: 18420820
Sci Rep. 2017 May 31;7(1):2530
pubmed: 28566683
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
Eur J Immunol. 2000 Mar;30(3):848-57
pubmed: 10741401
J Immunol. 2009 Jun 15;182(12):7353-63
pubmed: 19494257
Sci Immunol. 2017 Jan 6;2(7):
pubmed: 28783666
Front Immunol. 2018 Jul 30;9:1770
pubmed: 30131803
Sci Immunol. 2019 Apr 5;4(34):
pubmed: 30952804
PLoS One. 2011 Jan 26;6(1):e16333
pubmed: 21298114
Immune Netw. 2018 Oct 17;18(5):e33
pubmed: 30402328
Immunity. 2008 May;28(5):710-22
pubmed: 18468462
J Immunol. 2002 Mar 1;168(5):2240-6
pubmed: 11859111
J Virol. 1998 Aug;72(8):6637-45
pubmed: 9658110
Nat Immunol. 2020 Mar;21(3):309-320
pubmed: 31953534
J Exp Med. 2019 Dec 2;216(12):2748-2762
pubmed: 31558615
J Immunol. 2015 Jul 1;195(1):203-9
pubmed: 26026054